{‘She has zero qualifications’: the US medical establishment girds for Høeg's tenure at the FDA.

As the US proceeds with historic adjustments to its vaccine schedules, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by casting doubt on Covid shots throughout the global health crisis and has concentrated on possible fatalities following Covid vaccination in her brief time at the FDA.

Planned Overhauls to Childhood Vaccine Program

Agency leaders were set to unveil radical changes to the pediatric vaccination calendar in December, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would put the US at odds with much of the world with no evidence for public health gain. This reveal has been pushed back until the coming year.

Rather than the top vaccines chief, Høeg is scheduled to speak at the event. She was recently named interim head of the FDA’s CDER, the fifth appointee to run the division this calendar year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing some childhood shot schedules in the US to become more similar to Denmark's approach, a society with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Doubts Over Background

Høeg has no obvious track record in medication creation, regulation or leadership, which has been typical for former leaders of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in leading a major agency. She is not an expert in industry regulation.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that previous people who headed CBER have had.”

This division has an vast workload at the agency, the former commissioner pointed out.

“Many people just focuses on the new drug program, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and every single one need to be supervised,” Dr. Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a significant leadership aspect to the role, which oversees in excess of 5,000 personnel. “It is a massive management job, if you do it right,” Woodcock added.

Official Statement and Disputed Policies

Regarding concerns about Dr. Høeg's qualifications and whether this selection indicates increased cooperation among regulatory chiefs on immunizations, a spokesperson stated that the “questions stem from inaccurate assumptions”.

“Her resume matches the functions of her position,” the official said, citing the months Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a contentious one-day drug-approval program that apparently troubled her predecessors. “How are these therapies being selected for this voucher program? Who is making the calls?” Howard said. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards less stringent rules of most medications, aside from shots.”

Documented Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if problematic, past, Howard observe. She authored a research paper using non-validated public submissions to assess the incidence of myocarditis after COVID-19 immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the incoming government featured altering regulations for novel immunizations and halting “non-essential” immunizations, she remarked following the vote on a podcast. At the FDA, Høeg has allegedly suggested barring young men from obtaining COVID-19 vaccines.

“She’s an all-around true believer who begins with her preconceived notions and tailors the evidence to fit the evidence in a very deceptive, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|